Ignite Creation Date:
2024-05-06 @ 6:25 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05657691
Status:
COMPLETED
Last Update Posted:
2024-07-10
First Post:
2022-10-17
Brief Title:
Xanamem in Adults With Major Depressive Disorder and Impaired Cognition XanaCIDD
Sponsor:
Actinogen Medical
Organization:
Actinogen Medical
Study Overview
Official Title:
XanaCIDD A Double-Blind Randomized Placebo Controlled Parallel-Group Trial to Assess the Safety Tolerability and Efficacy of Xanamem in Adults With Major Depressive Disorder and Impaired Cognition
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Xanamem is being developed as a potential treatment for symptomatic early stages of Alzheimers Disease AD and Major Depressive Disorder MDD
This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem in treating patients with cognitive and depressive symptoms Trial participants will be randomized to either receive 10mg of Xanamem once daily or a Placebo at a 11 ratio in a double-blinded fashion
This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem in treating patients with cognitive and depressive symptoms Trial participants will be randomized to either receive 10mg of Xanamem once daily or a Placebo at a 11 ratio in a double-blinded fashion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None